Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596024 · ClinicalTrials.gov registry record · Phase 2
Lutein and Alzheimer's Disease Study
A Phase 2 study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00596024: Clinical Trial Phase 2 study, sponsored by Oregon Health and Science University.
NCT00596024 is a Phase 2 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00596024, a Phase 2 study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxidants that have important functions for human health. Carotenoids are known to reduce oxidative damage, but their effects have not been studied in AD patients. The objective of the study is to examine whether lutein supplementation helps to reduce oxidative damage from free radicals in AD patients.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT lutein/zeaxanthin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Why NCT00596024 stopped before completion
NCT00596024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00596024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00596024 about?
NCT00596024 is a clinical study titled "Lutein and Alzheimer's Disease Study". Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxid...
What is the current status of trial NCT00596024?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2007-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00596024?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), lutein/zeaxanthin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00596024?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00596024's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia